title: Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.
abstract: Lopinavir/ritonavir (LPV/r) is considered by many as the first choice protease inhibitor (PI) for children. This co-formulation avoids the need for children to take ritonavir separately to "boost" the levels of lopinavir. LPV/r has high virologic potency, an excellent toxicity profile and a high barrier to the development of viral resistance. However, LPV/r has poor tolerability of the oral suspension (due to the poor taste of ritonavir), difficult dosing requirements and metabolic side effects, especially hyperlipidemia. The new tablet low-dose formulation (100/25 mg) may allow more convenient antiretroviral treatment in children. Novel strategies of LPV/r in childhood could maximize its advantages. For example, infants infected with HIV despite single dose Nevirapine after birth need effective combination antiretroviral treatment. This can be given using a higher dose of LPV/r with therapeutic drug monitoring. Other novel uses include once daily LPV/r regimens in older children and adolescents and lower doses of LPV/r in certain populations, which may decrease hyperlipidemia. Heavily pre-treated children might benefit from a double PI/r regimen which includes LPV/r. The high potency of LPV/r needs to be balanced with convenient regimens, to enhance adherence and decrease toxicity whenever possible. The aim of this review is to discuss the rationale behind these novel strategies of LPV/r use in pediatric antiretroviral treatment as well as their results and limitations.
authors.affiliation: Laboratorio Inmuno-Biología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: Beatriz Larru
authors.initials: BL
authors.lastname: Martinez
authors.forename: F Andrew I
authors.initials: FA
authors.lastname: Riordan
references.citation: Antivir Ther. 2008;13(8):1087-90
references.pmid: 19195335
references.citation: Pediatrics. 2007 May;119(5):e1116-20
references.pmid: 17420261
references.citation: Lancet. 2007 Jul 7;370(9581):68-80
references.pmid: 17617274
references.citation: J Antimicrob Chemother. 2009 Oct;64(4):674-9
references.pmid: 19643777
references.citation: J Antimicrob Chemother. 2009 Nov;64(5):1080-6
references.pmid: 19729375
references.citation: Antivir Ther. 2008;13(3):375-80
references.pmid: 18572750
references.citation: Antivir Ther. 2006;11(4):439-45
references.pmid: 16856617
references.citation: J Antimicrob Chemother. 2006 Jun;57(6):1168-71
references.pmid: 16606636
references.citation: Ther Clin Risk Manag. 2008 Oct;4(5):1023-33
references.pmid: 19209283
references.citation: Antivir Ther. 2009;14(2):241-8
references.pmid: 19430099
references.citation: J Antimicrob Chemother. 2009 Aug;64(2):434-5
references.pmid: 19474068
references.citation: Curr Opin Infect Dis. 2009 Jun;22(3):256-63
references.pmid: 19405216
references.citation: Lancet. 2006 Aug 5;368(9534):424
references.pmid: 16890808
references.citation: Antivir Ther. 2009;14(4):603-6
references.pmid: 19578247
references.citation: Pediatr Infect Dis J. 2008 Jul;27(7):623-8
references.pmid: 18520443
references.citation: Drugs. 2006;66(9):1275-99
references.pmid: 16827606
references.citation: HIV Med. 2009 Nov;10(10):591-613
references.pmid: 19878352
references.citation: N Engl J Med. 2008 Nov 20;359(21):2233-44
references.pmid: 19020325
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9
references.pmid: 19451297
references.citation: Pediatr Infect Dis J. 2006 Sep;25(9):809-14
references.pmid: 16940839
references.citation: Antivir Ther. 2007;12(4):453-8
references.pmid: 17668553
references.citation: HIV Med. 2004 Jul;5 Suppl 2:61-86
references.pmid: 15239717
references.citation: J Antimicrob Chemother. 2009 Jul;64(1):118-25
references.pmid: 19420019
references.citation: Pediatr Infect Dis J. 2006 May;25(5):420-6
references.pmid: 16645506
references.citation: J Infect Dis. 2006 Apr 1;193(7):954-62
references.pmid: 16518757
references.citation: Pediatr Infect Dis J. 2006 Jun;25(6):533-7
references.pmid: 16732152
references.citation: J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):153-60
references.pmid: 16951643
references.citation: Antivir Ther. 2005;10(2):301-7
references.pmid: 15865224
references.citation: J Clin Virol. 2005 Aug;33(4):319-23
references.pmid: 16036182
references.citation: AIDS. 2008 Jan 11;22(2):F1-9
references.pmid: 18097218
references.citation: J Infect Dis. 2004 Jan 15;189(2):265-72
references.pmid: 14722892
references.citation: HIV Med. 2009 Oct;10(9):536-47
references.pmid: 19785664
references.citation: Pediatr Infect Dis J. 2003 Mar;22(3):216-24
references.pmid: 12634581
references.citation: Pediatr Infect Dis J. 2005 Oct;24(10):874-9
references.pmid: 16220084
references.citation: Arch Dis Child. 2009 Jan;94(1):70-4
references.pmid: 18838416
references.citation: AIDS. 2008 Jul 11;22(11):1333-43
references.pmid: 18580613
references.citation: J Antimicrob Chemother. 2007 Aug;60(2):436-9
references.pmid: 17556354
references.citation: HIV Med. 2010 Feb;11(2):137-42
references.pmid: 19682100
references.citation: Antimicrob Agents Chemother. 2006 Mar;50(3):910-6
references.pmid: 16495250
references.citation: Pediatr Infect Dis J. 2008 May;27(5):431-7
references.pmid: 18382386
references.citation: JAMA. 2006 Jul 19;296(3):330-1
references.pmid: 16849666
references.citation: N Engl J Med. 2001 Nov 22;345(21):1522-8
references.pmid: 11794218
references.citation: J Acquir Immune Defic Syndr. 2010 Jan;53(1):28-35
references.pmid: 19797972
references.citation: Pediatr Infect Dis J. 2006 Nov;25(11):987-94
references.pmid: 17072119
references.citation: Lancet Infect Dis. 2008 Aug;8(8):477-89
references.pmid: 18652994
references.citation: AIDS. 2008 Jan 30;22(3):385-93
references.pmid: 18195565
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83
references.pmid: 18625762
references.citation: Pediatr Infect Dis J. 2004 Jun;23(6):536-43
references.pmid: 15194835
references.citation: AIDS. 2008 Jan 11;22(2):249-55
references.pmid: 18097227
references.citation: J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10
references.pmid: 17224848
references.citation: N Engl J Med. 2007 Jan 11;356(2):135-47
references.pmid: 17215531
references.citation: J Antimicrob Chemother. 2008 May;61(5):1145-53
references.pmid: 18285316
references.citation: Pediatr Infect Dis J. 2009 Mar;28(3):215-9
references.pmid: 19209098
references.citation: HIV Med. 2005 Nov;6(6):421-5
references.pmid: 16268824